

CURRICULUM VITAE - GABRIEL P LASALA, MD, FACC

EDUCATION:

- Medical School: National University of Cordoba, Cordoba, Argentina
February 1978 – March 1984
Physician and Surgeon 12-19-83
- Internship: Posadas National Hospital, Buenos Aires, Argentina
Anesthesiology
March 1985 – March 1986
- Residency: Posadas National Hospital, Buenos Aires, Argentina
Internal Medicine
March 1986 – March 1988
- Internship: University of Mississippi Medical Center, Jackson, MS
Internal Medicine
January 1989 – January 1990
- Residency: University of Mississippi Medical Center, Jackson, MS
Internal Medicine
January 1989 – December 1991
- Fellowship: University of Mississippi Medical Center, Jackson, MS
Cardiology
January 1992 – December 1994

CURRENT POSITIONS:

- 06/2006 - Present. President and Founder - TCA Cellular Therapy, LLC. Covington, LA 70433
- 09/2005 - Present. Medical Director- LifeSource Cryobank, llc. Covington, LA 70433
- 05/2006 - Present. President and Founder - ProHealth, Covington, LA 70433
- 08/1998 - Present. President and Founder- Tchefuncte Cardiovascular Associates
- 07/2002 - Present. President and Founder- TCA Research, Covington, LA 70433
- 07/2009 - Present. President and Founder -Stem Cell Foundation, Covington, LA 70433

ADMINISTRATIVE POSITIONS:

Medical Director of Cardiac Catheterization Lab, Byrd Regional Hospital, Leesville, LA
January 1995 – September 1997

Medical Director of ICU, Byrd Regional Hospital, Leesville, LA
January 1997 – September 1997

President, Tchefuncte Cardiovascular Associates, Covington, LA
August 1998 – Present

Chief of Cardiology, St. Tammany Parish Hospital, Covington, LA
January 2001 and January 2002

Chief of Cardiology, Lakeview Regional Medical Center, Covington, LA
January 2001 and January 2002

Secretary of Treasure, St. Tammany Parish Hospital, Covington, LA
January 2003 – December 2003

Medical Director of Cardiac Catheterization Lab, Lakeview Regional Medical Center, Covington, LA
July 2003 - Present

Vice Chief of Staff, St. Tammany Parish Hospital, Covington, LA
January 2004 – December 2004

Chief of Staff, St. Tammany Parish Hospital, Covington, LA
January 2005- December 2005

Member of Executive Committee, St. Tammany Parish Hospital, Covington, LA
January 2006- Present

ACADEMIC POSITIONS:

Assistant Instructor of Physiology, National University of Cuyo School of Medicine, 1981-1982

Instructor of Medicine, University of Mississippi Medical Center, Jackson, MS
January 1990 – January 1995

ACLS Instructor,. American Heart Association. February 1994 - Present

Rotational Coronary Atherectomy: Proctor for Rotablator, Boston Scientific-SCIMED Corp.
April 2000 – Present

Clinical Assistant Professor in the Department of Medicine, Tulane University, New Orleans, LA
October 2005- Present

PUBLICATIONS:

- 1) J. Abdhala, M. Delugan, G Perez Lasala. Effects of beta adrenergic blocker agents on vascular reactivity. Rev Univ 87,7:1998:84
- 2) G. Perez Lasala. Fibrinolytics in the treatment of acute Myocardial Infarction. Prensa Med Argentina 75;8, 1998:270-73
- 3) W. Bennet, L. Farias, G. Perez Lasala. Mechanical function of ex-vivo cold stored hearts is improved with fructose 1-6 diphosphate. Clinical Research. 38,1;1990:24A
- 4) G. Perez Lasala, R. Nolan, S. Chapman Peritoneal blastomycosis. Am j. Gastroent. 86,3;1991:357-359
- 5) T. Wright, L. Farias, G. Perez Lasala Plasma oxidase assay for diagnosis of myocardial infarction. Clinical Research 39, 4; 1991:799A
- 6) G. Perez Lasala, T. Cannon, K. Mansel. Lymphangitic carcinomatosis from cervical carcinoma. Am J Med Sci 303(3); 1992:174-76
- 7) E. Abbud, K Osman, G. Perez Lasala. Possible mechanism for the appearance of J-wave on the electrocardiogram during hypothermia. Eur Heart J 13: (suppl); 1992:112
- 8) J.D. Cleary, J. Hayman, J. Sherwood, G. Perez Lasala, T. Piazza-Hepp. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 27;1993:715-
- 9) G. Perez Lasala, T. Wright, K. Osman, S. Siouffi, T. Skelton. Plasma oxidase assay for screening of myocardial infarction. AM J Med Sci 1994; 308(3): 157-161
- 10) S Nissen, JC Tardif, G Lasala. Effect of Torcetrapib on the the progression of coronary artery disease. N Engl J Med , 2007 356(13):1304-1316
- 11) G Lasala, J Minguell. Bone Marrow derived progenitor cells: Their use in clinical studies for the treatment of myocardial infarction. Heart, Lung and Circ 2009; 18:171-180

SUBMITTED

- 12) José J Minguell, PhD^{1,2*}, Fernando M Florenzano, MD³, Gabriel P Lasala, MD². The intracoronary infusion of a combination of bone marrow-derived stem cells in dogs is safe and feasible. Submitted for publication.
- 13) G Lasala, J Silva, J Minguell. Combination stem cell therapy for the treatment of severe coronary ischemia. Submitted for publication.
- 14) G Lasala, J Silva, J Minguell. Combination of stem cell therapy for the treatment of severe limb ischemia. Submitted for publication

PRESENTATIONS:

Effects of beta-adrenergic blocking agents in vascular reactivity.
Jornadas Nacionales de Investigacion. Mendoza, Argentina. 1984

Peritoneal Blastomycosis. American College of Physician. Louisiana and Mississippi Scientific Meeting. Jackson, Mississippi. 1990

Plasma Oxidase Activity. Southern Society for Clinical Investigation. New Orleans, Louisiana. 1992

Plasma Oxidase assay for diagnosis of myocardial infarction. American College of Physicians. 73rd Annual Session, San Diego, CA. 1992

Early Diagnosis of myocardial infarction. American College of Physician. 74th Annual Session. 1993

Combination Stem Cell Therapy for the treatment of severe coronary ischemia The 5th Annual International Conference on Cell Therapy for Cardiovascular Diseases. New York, NY 2009.

Combination Stem Cell Therapy for severe limb Ischemia. A Phase I trial. American College of Cardiology Annual Meeting Orlando, FL 2009

Combination Stem cell therapy for severe coronary ischemia. Preliminary results from Phase I/II trial. European Congress of Cardiology. Barcelona Spain 2009

Combination Stem cell therapy for severe limb ischemia. Phase I/II Trial. European Congress of Cardiology. Barcelona, Spain 2009

Combination Stem Cell Therapy for the treatment of severe limb ischemia. World Stem Cell Summit, Baltimore, Maryland. 2009

AWARDS:

Certificate of Merit. American College of Physicians: Jackson, MS. 1990

Certificate of Merit. American College of Physicians: San Diego, CA 1992

Top Doctors. New Orleans Magazine. New Orleans, LA 2007

Health Care Hero. City Business. New Orleans, LA 2008

Top Doctors. Living Magazine. North Shore, LA. 2009

RESEARCH EXPERIENCE IN CLINICAL TRIALS:

2009 – Present – Investigator – Combination Stem Cells Therapy for the Treatment of Severe Myocardial Ischemia – Phase II. TCA Cellular Therapy

2008 – Present – Investigator – Acuarius - Novartis

2008 – Present – Investigator – Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia – Phase II. TCA Cellular Therapy

2008 – Present – Investigator -. Saturn. AztraZeneca

2008 – 2009 – Investigator – Combination Stem Cells Therapy for the Treatment of Severe Myocardial Ischemia – Phase I. TCA Cellular Therapy

2007 – 2008 – Investigator – Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia – Phase I. TCA Cellular Therapy

2007 – 2009 – Investigator - Combination Stem Cell Therapy for Utilization and Rescue of Infarcted Myocardium – TCA Cellular Therapy

2005 – Present - Investigator – Protocol EFC5827 – Sanofi-Aventis

2005 – 2006 – Investigator – DEScover Registry - Cordis

2005 – Present – Investigator – Protocol A5091043 – Pfizer

2005 – 2006 – Investigator – Protocol A5091018 - Pfizer

2004 – Present – Investigator – Options Study – Protocol IDE # G030031 – Biotronik

2003 – 2006 – Investigator – IVUS Study – Protocol A5091005 – Pfizer

2003 – Present – Subinvestigator – Jupiter Study – Protocol 422US/0011 – AstraZeneca

2002 – 2006 – Subinvestigator – Charisma Study – Protocol EFC4505 – Sanofi-Synthelabo/Bristol - Myers Squibb

2000 – 2002 – Subinvestigator – Comply Study – Protocol 1999052 – Procter & Gamble

2000 – 2002 – Subinvestigator – Comma Study – Protocol 1999053 – Procter & Gamble

2000 – 2001 – Subinvestigator – Octave Study – Protocol CV137-120 – Bristol-Meyers Squibb

2000 – 2002 – Subinvestigator – Sportif V Study – Protocol 233 – Astra Zeneca

1999 – 2001 – Subinvestigator – Bravo Study – Protocol SB 214857 – Smith Kline Beecham

1998 – 2000 – Subinvestigator – Azimilide Study – Protocol 1998018 – Procter & Gamble

SOCIETY MEMBERSHIPS:

American College of Cardiology

American Heart Association

American College of Phlebology

Louisiana State Medical Society

European Society of Cardiology

International Society for Cellular Therapy

Stem Cell Portal

International Cellular Medicine Society

Adult Stem Cell Research Network

International Society for Stem Cell Research

The International Cellular Medicine Society

The ALS association